AV-380 is under clinical development by AVEO Pharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AV-380’s likelihood of approval (LoA) and phase transition for Cancer Anorexia-Cachexia Syndrome took place on 30 Mar 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AV-380 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AV-380 is under development for treatment of cancer associated cachexia. It acts by targeting growth differentiation factor 15 (GDF-15) which is also known as macrophage inhibitory cytokine-1. It is developed based on human response technology. It is administered through intravenous route.
AVEO Pharmaceuticals overview
AVEO Pharmaceuticals (AVEO), is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of various types of cancers. Its flagship product tivozanib is approved as a first-line treatment for adult patients with renal cell carcinoma and marketed under the brand name Fotivda in European Union, Iceland and Norway. The company’s clinical product includes Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, and AV-203, an anti-ErbB3 monoclonal antibody. It also has pre-clinical products in the pipeline. The company develops products through strategic partnerships with other pharmaceutical companies. AVEO is headquartered in Boston, Massachusetts, the US.
Quick View AV-380 LOA Data
|Highest Development Stage|